Study Finds on MSN

New Kidney Treatments Show Promise, But Results Remain Frustratingly Mixed

Kidney research reveals a complex picture of life-saving treatments that show genuine promise but deliver frustratingly mixed ...

Compass Therapeutics Provides Corporate Update

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) ...